Covid-19 variant PJ.2.1: symptoms, vaccine, and spread explained

A new Covid-19 variant, PJ.2.1, has been detected in multiple countries, but there is no convincing evidence it causes more severe illness, hospitalizations, or deaths than other variants. First documented in Ontario, Canada, in May, PJ.2.1 has since been reported in the US, Spain, France, Israel, Singapore, Australia, and New Zealand. Early lab findings suggest its spike protein may bind more effectively to human cells, potentially aiding spread, though real-world transmissibility remains under investigation. Reported symptoms resemble a cold or flu, including sore throat, fever, and fatigue. Research indicates current vaccines can neutralize the variant, though it is slightly less sensitive to antibodies. The WHO is monitoring the variant and advises vaccination for vulnerable groups.